(Q33398183)

English

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

chronic myeloid leukemia

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Andreas Hochhaus

object named as

A Hochhaus

3

0 references

Jorge Eduardo Cortes

object named as

J Cortes

10

1 reference

ORCID Public Data File 2021

author name string

P D le Coutre

1

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

F J Giles

2

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

J F Apperley

4

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

G J Ossenkoppele

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

R Blakesley

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Y Shou

7

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

N J Gallagher

8

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

M Baccarani

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

H M Kantarjian

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

publication date

11 November 2011

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

26

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1189-1194

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

https://scigraph.springernature.com/pub.10.1038/leu.2011.323

0 references

The biology of chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Characteristics of accelerated disease in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

The long-term durability of cytogenetic responses in patients with accelerated phase chronic myeloid leukemia treated with imatinib 600 mg: the GIMEMA CML Working Party experience after a 7-year follow-up

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Staging of chronic myeloid leukemia in the imatinib era: an evaluation of the World Health Organization proposal

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Structural resemblances and comparisons of the relative pharmacological properties of imatinib and nilotinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Harmonization of molecular monitoring of CML therapy in Europe

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Deletion of the alternatively spliced fibronectin EIIIA domain in mice reduces atherosclerosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Sustained durability of responses and improved progression-free and overall survival with imatinib treatment for accelerated phase and blast crisis chronic myeloid leukemia: long-term follow-up of the STI571 0102 and 0109 trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia pos

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

21 January 2018

Frequency and clinical significance of BCR-ABL mutations in patients with chronic myeloid leukemia treated with imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2011.323

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1038/LEU.2011.323

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33398183&oldid=1639501465"